5.
On p10, the authors indicate that "a specialist will receive an alert and contact the patient within 24 hours". What type of specialist? How feasible is this in terms of number of patients? Will specialists be available to call that patient within 24 hours whatever day of the week the PROs are completed? 6.
This RCT randomised patients. Hence the same specialists will be seeing the control group patients. what checks will be in place to ensure that contamination across the 2 groups does not occur, ie that specialists don't change their regular care of non-intervention patients? Can specialists access the PRO scores of ALL patients, or only intervention patients? 7.
P11 details the participant withdrawal criteria. Please provide some details as to why #3 is a criterion. Also please provide a couple of examples in brackets e criterion #7. 8.
The data analyses are described on p13. With the large number of PRO collection time points (p10), please detail the potential maximum number of comparisons that will be made and what adjustment, if any, in p value should be made to account for potential Type I error? Some input from a statistician is required. 9.
On p14, the authors state that they will "provide all participants with free long-term medical consultation after this study". Is this different to usual care -ie would lung cancer patients usually have to pay for any follow-up care? If so, then please comment on how this may be seen as an enticement to participate in the study and what ethical implications this may have.
10.
On p14, the authors state that they "will inform the applicants of the results". Who are the "applicants"? 11.
On p14, the authors state that they have no plans to disseminate the results to participants. This seems to differ from usual expectations of ethics committees. Please clarify the reasons for non-communication of results to participants. 12.
The protocol should include a Discussion section to detail the potential implications of the predicted findings. 13 .
In the SPIRIT guide, p10 does not actually provide any detail re points 11c or 22. 14.
Some strengths and one limitation are provided on p5. Depending on the authors' responses to the comments provided above, they may consider addition of further limitations.
1. I don't think the description of the intervention itself is comprehensive enough at present and more detail is required. For example, if patients have the option of completing electronically, how do they do this? On a special device or their own devices? How is PRO reporting managed after discharge from hospital? Are patients completing on paper and posting them back? How are clinicians alerted to severe responses? Particularly those completed on paper. 2. In the current description, there isn't a very clear distinction between the intervention and control. If they are completing on the same schedule and control group patients are being advised (rightly so) to seek medical help for severe symptoms reported, is the only distinction that the alerts are sent to clinicians for the intervention group? This needs to be clarified, and the implications need to be discussed. 3 . The authors state that severe postoperative complications affecting symptom data collection will be criteria for withdrawal. Does this include patients who are too unwell to complete? What happens in this instance? Are patients immediately withdrawn or is this treated as missing data? 4. In addition, authors state intention to treat analysis will be undertaken but also state that if a patient meets withdrawal criteria, no data will be included in analysis. Could this be clarified? 5. Could the authors please clarify why patients with a history of neoadjuvant treatment are excluded? 6. Could the authors please include some discussion of the limitations of using the same measure for the PRO intervention as for the outcome? 7. Could the authors please include some discussion or justification of not involving patients in the development or design of the study? Introduction Quite a bit of space in the introduction is dedicated to PRO measurements prolonging survival. Is this specifically in the chemotherapy population who are alerting professionals to signs of a serious complication such as neutropenic sepsis, or is this something you might expect to be of relevance to the postoperative lung cancer population? Survival doesn't seem to be an outcome in this study. Line 137: the authors mention that they have conducted an observational study of perioperative symptom management in patients with lung cancer based on PROMs, and this randomised controlled trial follows on from it. Can they share any preliminary results in the introduction to make the case for this trial e.g. were there particular problems with symptom management in their observational study during the early post-operative phase? Did many of the participants have symptoms that would have exceeded threshold in this study? Did they use the data to inform frequency of PRO monitoring? The hypothesis is that "patients undergoing PRO-based symptom monitoring have a lower symptom burden that those undergoing standard symptom management". This seems to miss a few steps: is the theory that patients undergoing PRO based symptom monitoring get more medical input after surgery, and increased symptom management advice/pharmacological therapies from their clinicians, hence lowering symptom burden? In other words, patients who are not being monitored do not tend to seek medical attention despite experiencing problematic symptoms? Methods: Participants: The authors might give a few lines explaining their inclusion criteria e.g. why limit the study to under 75 year olds? Why exclude people who have had neo-adjuvant therapy if the study is specifically about symptom control? Will all the patients have non small cell lung cancer or is early stage small cell lung cancer included? It would also be useful, particularly for nonsurgeons and international readers to understand the types of lung cancer surgery that the sample population are likely to be receiving. Sample size calculation: "mean threshold event" is defined later under the "primary outcomes" section, but it would be useful to give the definition here. Randomisation, allocation concealment, and blinding: it will not be possible to blind clinicians and participants, but why is it not possible to blind investigators on the research team? Will statisticians/those analysing the results be blinded to the group? Intervention procedure: some more detail about an "equestionnaire" is given in "data collection, management, and quality control" later in the paper, but I still wasn't clear whether the questionnaire would be done on-line via personal devices (is internet access an inclusion criteria/access to a smartphone or computer), is there a secure login e.g. a portal system? It would be important to describe the SMARS in detail here: how is the Symptom Monitoring Alerting and Response System applied? In what format(s) are PRO data collected? Who administers the PRO? Will this change between in-hospital versus post discharge assessments? Are the alerts automatic e.g. within an electronic PRO assessment and generated/fed back to the specialist contemporaneously/ by email, or does this require interpretation by someone else? Are they fed back in the form of narrative reports or graphs? What type of specialist will receive the alert e.g. oncologist? Will the specialist be given any guidelines to standardise the way that symptoms are managed within the study or will this vary by specialist and institution? Are patients informed about the threshold levels? This might influence their responses e.g. if they know that the threshold is 4 and do not want medical help with that symptom they may choose "3". What steps will be taken to monitor intervention fidelity? This has been a problem in other randomised controlled trials of PRO interventions (see Adam Secondary outcomes: will the authors look at differences in prescribed therapies between the groups? Is there any scope to assess the workload of this intervention for patients or patient/clinician satisfaction with the system/acceptability? Patient and public involvement: is free long-term medical consultation an incentive to take part? The authors state that they do not plan to feed back results to participants but give no explanation as to why this would be the case.
VERSION 1 -AUTHOR RESPONSE
Replies to Reviewer 1: Afaf Girgis 1. The introduction provides a brief overview of the literature on use of PROs, largely focused on studi es conducted by Basch in the USA (p6 & 7). There is a significant body of research which has been c onducted in the UK and Australia for example, dating back to the 1990s to current, which should be re ferenced, to provide a balanced overview of the literature. 2. On p8, the authors indicate that participants will be recruited from 6 tertiary hospitals. However, no details are provided regarding how eligible patients will be identified, and by whom, how and when rec ruitment will be undertaken. Response: Participants will be recruited from in-hospital patients. The participating clinicians will perform the recruitment using the inclusion criteria and exclusion criteria before the surgery. Eligible patients should meet all the inclusion criteria and not meet any of the exclusion criteria (Page 9).
3. Furthermore, point 15 of the SPIRIT guide says "none" to issues relating to participant enrolment, w hich is surprising as every trial should really have some strategies for achieving adequate participant enrolment to reach the required sample size! Point 18b refers the reader to p11 for details re promotin g participant retention, but there are in fact no details about this in the protocol. This needs to be rectif ied. Response: Strategies for achieving adequate participant enrolment to reach a target sample size include inviting more doctors in each centre to participate in the study and adding more research centres (point 15). Plans to promote participant retention and complete follow-up include education, refill reminders, and commitments to provide all the patients with free long-term medical consultations after the trial (point 18b). The correction has been made in the revised manuscript (Page 9).
4. On p9, the sample size calculation is based on 20% retention. A) is this figure based on previous re search, or published work with these populations or if not, then what? B) does this 20% figure include both loss to followup AND withdrawal? If so, the figure is perhaps low given this population? Need to justify. Response: The 20% attrition rate is based on our ongoing observational research (NCT03341377). The current withdrawal rate is about 17% in the observational research. The rate of loss to follow-up in this trial is estimated to be less than 3%, because this trial is an interventional study and the followup time is very short (less than 4 weeks). Therefore, in this trial, the 20% attrition include both withdrawal and loss to follow-up.
5. On p10, the authors indicate that "a specialist will receive an alert and contact the patient within 24 hours". What type of specialist? How feasible is this in terms of number of patients? Will specialists be available to call that patient within 24 hours whatever day of the week the PROs are completed?
Response: Specialist is a participating thoracic surgeon. WeChat is the most popular social software in China, covering about 90% of the smartphone (reference#29). Currently, we have already followed up more than 1000 patients through a mobile medical application (Tencent Trusted Doctors) and the patient's WeChat. It takes about 20 minutes of fragmented time per day to answer the patient's questions. It can be very efficient to manage the patient's symptoms via various templates of text message, voice message, and videos. In this trial, we will use an electronic PRO system (ePRO Hub). After enrolment, patients will use their WeChat app to connect with the participating specialists' WeChat app via a mini program (ePRO Cell). It will be more efficient, because ePRO Hub can send e-questionnaires, e-reminders, and e-alerts automatically (Figure 1) . It also has various templates to manage the patient's symptoms via WeChat app. In addition, the follow-up time is less than 4 weeks in this trial. Therefore, it is feasible and the specialist is available to contact the patient within 24 hours whatever day of the week.
6. This RCT randomised patients. Hence the same specialists will be seeing the control group patient s. what checks will be in place to ensure that contamination across the 2 groups does not occur, ie th at specialists don't change their regular care of nonintervention patients? Can specialists access the PRO scores of ALL patients, or only intervention pati ents? Response: All the electronic PRO (ePRO) data will be directly uploaded to the research electronic data capture (REDCap) platform. The control group patients' ePRO data will not be accessed by the specialists. Specialists can only access the ePRO scores of the intervention group patients (Page 14).
7. P11 details the participant withdrawal criteria. Please provide some details as to why #3 is a criterio n. Also please provide a couple of examples in brackets e criterion #7. Response: As to withdrawal criteria #3, patient with a postoperative hospital stay > 14 days usually has a severe compliation, and the patient compliance will gradually decrease, which will affect the accuracy of PRO data. As to withdrawal criteria #7, patient seriously violates the study protocol, including continually not complying with the specialist's advice, intentionally letting a proxy to complete the PRO surveys, and deliberately providing false PROs (Page 12). The correction has been made in the revised manuscript.
8. The data analyses are described on p13. With the large number of PRO collection time points (p10) , please detail the potential maximum number of comparisons that will be made and what adjustment, if any, in p value should be made to account for potential Type I error? Some input from a statistician i s required. Response: In this trial, there is only one primary outcome, the average number of over-thresholds events on targeted symptoms, for which one comparison will be conducted to evaluate the efficacy of the SMARS. One of our corresponding authors, Dr. Qiuling Shi, is an experienced statistician for PRO data. She has been in charge of data analysis for multiple oncological trials with PRO as outcomes (Reference #17: Cleeland CS, Wang XS, Shi Q, et al. Automated symptom alerts reduce postoperative symptom severity after cancer surgery: a randomized controlled clinical trial. J Clin Oncol 2011;29:994-1000).
9. On p14, the authors state that they will "provide all participants with free longterm medical consultation after this study". Is this different to usual care -ie would lung cancer patient s usually have to pay for any followup care? If so, then please comment on how this may be seen as an enticement to participate in the s tudy and what ethical implications this may have. Response: In China, the first clinic visit of surgical lung cancer patient is approximately 4 weeks after discharge. There is no usual follow-up within these 4 weeks after discharge. In addition, usual care does not include free medical consultation after discharge. Patients usually have to pay for follow-up care. This is an incentive for patients who participate in the study, which may promote participant retention. This incentive may do more good than harm to patients, so it is strongly recommended by the ethics committee of our hospital.
10. On p14, the authors state that they "will inform the applicants of the results". Who are the "applica nts"? Response: Applicants include the study participants, the public, and other researchers. They will be informed that they can obtain the final results of this study through our future published articles (Page 16).
11. On p14, the authors state that they have no plans to disseminate the results to participants. This s eems to differ from usual expectations of ethics committees. Please clarify the reasons for noncommunication of results to participants. Response: According to the regulation of the ethics committee of our hospital, participants can keep informed of the study information and research progress at any time during the study. However, the final results of this study will not be available at once. There is a time lag between the study completion and the final results published. The ethics committee does not mandate that we should disseminate the final results to participants. Participants will be informed if they apply for it in advance. Participants will also be informed that they can obtain the final results of this study through our future published articles (Page 16).
12. The protocol should include a Discussion section to detail the potential implications of the predicte d findings. Response: We have briefly stated the implications of the predicted findings of this study in the INTRODUCTION section (Pages 6-8). We have followed your advice to add a Discussion section to detail the potential implications of the predicted findings at the end of the article (Pages 16-17).
13. In the SPIRIT guide, p10 does not actually provide any detail re points 11c or 22. Response: An incentive strategy providing participants with free long-term medical consulation after this trial will be made to improve adherence (Page 9). Patients' adherence to the interventions will be asked at each time point. Those who do not follow the specialist's advice will be monitored, and the number of violations will be recorded. Those who refuse to follow the specialist's advice more than three times will be considered as seriously violating the study protocol and will be withdrawn (point 11c)(Page 11). We will also record and report the adverse events of the interventions if any. All the adverse events will be assessed and managed by a thoracic doctor (point 22)(Page 14). The correction has been made in the revised manuscript.
14. Some strengths and one limitation are provided on p5. Depending on the authors' responses to th e comments provided above, they may consider addition of further limitations. Response: We have added more limitations of this trial in the Discussion section at the end of this article (Page 17).
Replies to Reviewer 2: Dr Lorraine Warrington 1. I don't think the description of the intervention itself is comprehensive enough at present and mor e detail is required. For example, if patients have the option of completing electronically, how do they do this? On a special device or their own devices? How is PRO reporting managed after discharge fro m hospital? Are patients completing on paper and posting them back? How are clinicians alerted to se vere responses? Particularly those completed on paper. Response: Thank you for your valuable suggestion. We have added one item in the inclusion criteria, that is, # (5) able and willing to respond to a repeated electronic questionnaire on a smartphone or a tablet (Page 9). So, in this trial, all the patients will use electronic-based PRO measures. They will complete the ePRO questionnaires on a smartphone or a tablet (Pages 10-11). Paper-based PRO measures will not be used in this study. Correction has been made in the revised manuscript .
2. In the current description, there isn't a very clear distinction between the intervention and control. I f they are completing on the same schedule and control group patients are being advised (rightly so) t o seek medical help for severe symptoms reported, is the only distinction that the alerts are sent to cli nicians for the intervention group? This needs to be clarified, and the implications need to be discusse d. Response: Thank you for your constructive suggestion. While in hospital, the distinction between the intervention group and the control group is that the intervention group patients' medical interventions are based on the scores of the PROs rather than the doctor's own judgement. After discharge, there is no routine follow-up within 4 weeks in the usual care in China. According the study design, the control group patients will just report their PROs. They will not generate any alert emails or get responses relating to their symptoms. If they have severe symptoms, they will usually go to the nearest hospital. Therefore, after discharge, the symptom management of the intervention group patients are proactive and the traditional standard symptom management of the control group patients are passive and reactive. Correction has been made in the revised manuscript to address this issue (Pages 11-12).
3. The authors state that severe postoperative complications affecting symptom data collection will b e criteria for withdrawal. Does this include patients who are too unwell to complete? What happens in this instance? Are patients immediately withdrawn or is this treated as missing data? Response: In lung cancer surgery, severe postoperative complications mainly include respiratory failure, reoperation and death. The rate is less than 3% according our ongoing observational study (NCT03341377). Severe postoperative complications will affect the accuracy of PROs. So, it is listed as a withdrawal criteria. Patients who are too unwell to complete PRO usually ask to withdraw from the study initiatively. PRO data of patients meeting the withdrawal criteria will no longer be collected immediately (Page 12).
4. In addition, authors state intention to treat analysis will be undertaken but also state that if a patie nt meets withdrawal criteria, no data will be included in analysis. Could this be clarified? Response: Thank you for your valuable suggestion. We have made a mistake. Actually, We will conduct per-protocol analyses. Correction has been made in the revised manuscript (Page 14).
Could the authors please clarify why patients with a history of neoadjuvant treatment are exclude d?
Response: This trial aims to test the hypothesis that the PRO-based symptom monitoring, alerting, and response system (SMARS) will improve the quality of care on symptoms related to lung cancer surgery. The adverse effect as well as the potential increased surgical complications of neoadjuvant treatment may confound the symptom development after surgery. Thus, in the current trial, we will focus on homogenous patient population with surgery-related symptoms. In the future, pragmatic trials will be conducted to include patients with neoadjuvant treatment.
6. Could the authors please include some discussion of the limitations of using the same measure fo r the PRO intervention as for the outcome? Response: Treatment guidelines from the American Society of Clinical Oncology (ASCO) guidelines and the National Comprehensive Cancer Network (NCCN) use same symptom measures for both triggering clinical actions (≥4 on a 0-10 scale) and evaluating the quality of symptom control from those clinical actions (a <4 score referring to a well-managed symptom). Aiming to evaluate the benefit of SMAR system on perioperative symptom control, using the same measure and strategy recommended by those guidelines will provide clinically applicable evidence for symptom management in practice. 7. Could the authors please include some discussion or justification of not involving patients in the d evelopment or design of the study? Response: Both previous reports (Reference #11 and #17) and our ongoing observational study has provided pilot data for the development and design of this trial in terms of patients' willingness to be involved in and their compliance to a PRO-based study. According to our ongoing observational study, the current completion rate of PRO questionaires was 94.7% in hospital and 64.5% after discharge.
Replies to Reviewer 3: Rosalind Adam 1. A small point: surgery is "the" primary treatment for lung cancer. Would it be more accurate to state that it is "one" primary treatment or "a" primary treatment for lung cancer? Response: Thank you for your helpful suggestion. We have changed the sentence to 'surgery is one of the primary treatments for lung cancer' (Page 3).
2. Quite a bit of space in the introduction is dedicated to PRO measurements prolonging survival. Is th is specifically in the chemotherapy population who are alerting professionals to signs of a serious com plication such as neutropenic sepsis, or is this something you might expect to be of relevance to the p ost-operative lung cancer population? Survival doesn't seem to be an outcome in this study. Response: I agree with your perspective. A randomised controlled trial has already proved that proactive symptom management can improve survival in the chemotherapy population. However, this perspective has not been proved in the surgical population. In the first phase of our studies, we want to prove proactive symptom management can reduce symptom burden and improve quality of life (QOL). Theoretically, adequate postperative symptom control and improved QOL can ensure a timely return to intended oncologic therapy, and thus, a potential better survival. In the second phase of our future studies, survival will be an outcome (Page 7).
operative phase? Did many of the participants have symptoms that would have exceeded threshold in this study? Did they use the data to inform frequency of PRO monitoring? Response: Yes, we have been conducting an observational study of perioperative symptom in patients with lung cancer using MDASI-LC (NCT03341377). A mistake (been conducting not already conducted) has been corrected in the revised manuscript (Page 7). Because it is an ongoing study, we may not release the final results until the completion of the study. But you can get some preliminary results in the 2018 WCLC and 2019 WCLC ABSTRACTS by search with first author name 'WEI DAI'. Below are two figures and one abstract involving some preliminary results.
4.
The hypothesis is that "patients undergoing PRObased symptom monitoring have a lower symptom burden that those undergoing standard symptom management". This seems to miss a few steps: is the theory that patients undergoing PRO based sy mptom monitoring get more medical input after surgery, and increased symptom management advice/ pharmacological therapies from their clinicians, hence lowering symptom burden? In other words, pati ents who are not being monitored do not tend to seek medical attention despite experiencing problem atic symptoms?
Response: Yes, patients undergoing PRO based symptom monitoring will get more medical input after surgery, and hence, get a theoretical better symptom control and QOL. This is the hypothesized underneath mechanism of the symptom monitoring, alerting, and response system (SMARS) for improving post-operative symptom management. Besides the direct symptom outcomes, this RCT will provide high-level evidence to test this mechanism. Furthermore, it will help address whether PRObased postoperative symptom management is feasible and necessary after discharge, especially in China. Because there is no routine follow-up within 4 weeks after discharge in the usual care in China.
Last, it will lay a foundation for our future study on whether early-phase postoperative symptom management improves survival. Most importantly, this may bring huge potential benefits for patients, although it seems that more medical resources will be input. In the future, we will examine how the burden for healthcare system will be relieved as the development of technology, e.g. the widespread use of mobile medical application Response: In the real world, the rate of patients over 75 receiving lung cancer surgery is very low.
According to our ongoing, observational, and real-world study (NCT03341377), the current rate of patients over 75 receiving lung cancer surgery is 4.7%. In addition, the age range from 18 to 75 is based on international routine of clinical trial. Because the older the patient, the higher the postoperative complications and the worse their understanding of the study content. This may also affect the accuracy of PROs. Therefore, we exclude patients over 75. This trial aims to test the hypothesis that the PRObased symptom monitoring, alerting, and response system (SMARS) will improve the quality of care on symptoms related to lung cancer surgery. The adverse effect as well as the potential increased surgical complications of neoadjuvant treatment may confound the symptom development after surgery. Thus, in the current trial, we will focus on homogenous patient population with surgery-related symptoms. In the future, pragmatic trials will be conducted to include patients with neoadjuvant treatment. According to our inclusion criteria, both the non small cell lung cancer patients and small cell lung cancer patients will be included (Page 9).
6. Sample size calculation: "mean threshold event" is defined later under the "primary outcomes" secti on, but it would be useful to give the definition here.
Response: Thanks. We have placed the definition of mean symptom threshold events in the "Sample size calculation" section now (Page 9).
7. Randomisation, allocation concealment, and blinding: it will not be possible to blind clinicians and p articipants, but why is it not possible to blind investigators on the research team? Will statisticians/tho se analysing the results be blinded to the group?
Response: In this trial, the ePRO questionnaires will be set to send to the patients' WeChat automatically after randomisation. We will not blind clinicians and participants. However, there will be data collectors (medical students or research nurses) to help administer PRO collection in the actual practice. The data collectors will be blinded to group allocation to minimise measurement bias. In addition, the statisticians analysing the results will also be blinded to the group allocation (Page 10).
8. Intervention procedure: some more detail about an "equestionnaire" is given in "data collection, management, and quality control" later in the paper, but I sti ype of specialist will receive the alert e.g. oncologist? Will the specialist be given any guidelines to sta ndardise the way that symptoms are managed within the study or will this vary by specialist and institu tion?
Response: We have added one item in the inclusion criteria, that is, # (5) able and willing to respond to a repeated electronic questionnaire on a smartphone or a tablet (Page 9). So, in this trial, all the patients should have an internet access and will use electronic-based PRO measures. They will complete the ePRO questionnaires on their smartphone or tablet (Pages 10-11). Paper-based PRO measures will not be used in this study.
The SMARS (figure 1) includes a research electronic data capture (REDCap) platform used to store electronic PRO (ePRO) data, an ePRO system (ePRO Hub) used to generate e-questionnaires, alerts, and reminders automatically, a most popular social software (WeChat) in China used to manage patients' symptoms (Page 8). The following figure is a diagram of the SMARS.
The data collector, usually a medical student and a research nurse, will help administer PRO collection. For the intervention group, the participating specialist (thoracic surgeon) will receive e-alerts in the form of narrative reports. The symptom relief measures of the intervention group patients will comply with the latest guidelines and be standardised across all centres, in the form of a standard operating procedure handbook (Page 11).
9. Are patients informed about the threshold levels? This might influence their responses e.g. if they know that the threshold is 4 and do not want medical help with that symptom they may choose "3".
Response: Patients will not be informed about the threshold levels (Page 11). Response: Patients' adherence to the interventions will be asked at each time point. Those who do not follow the specialist's advice will be monitored, and the number of violations will be recorded. Those who refuse to follow the specialist's advice more than three times will be considered as seriously violating the study protocol and will be withdrawn (Page 11).
12.
Control group: what is "the standard symptom management procedure?" An international audience may have little to no knowledge of standard healthcare procedures in the setting of this study. The authors mention that clinicians will use their experience, but it's very difficult to get an impression of what procedures are in place. For example, are control patients given a specific named contact/ a telephone number? Do they go through a primary care physician? Do any/all of the hospitals have guidelines that clinicians follow? Will care vary on, for example, public/private systems? Do the patients have homecare nurses or community team input? Are they given any standardised education about symptom management postoperatively e.g. leaflets, other resources? Response: In China, standard symptom management procedures usually only relate to the hospitalization phase. During hospitalization, the doctors usually make patient rounds every morning and afternoon. They will evaluate and manage the patients' symptom based on their own judgement (Page 12). Upon discharge, the patients will receive standard education about symptom management. The surgical department' telephone numbers and leaflets are available. After discharge, the patients will go home and the first clinic visit is approximately 4 weeks later. These is a time interval between the discharge time and the first clinic visit time. During these time, the patient's symptoms will not be monitored. Homecare nurses or community team input are unavailable. If the patients have any severe discomfort, they will usually go to the nearest hospital (mainly public systems). Doctors always evaluate and manage the patients' discomfort based on their own experience and knowledge.
"participant recruitment" and plans to promote participant retention, but it would be important to explain that usual practice in China is to charge a fee for medical follow up after surgery, and to make it clear that free care is an incentive. Otherwise, I am happy that the changes to the protocol have provided clarity and addressed the peer review comments.
VERSION 2 -AUTHOR RESPONSE
Replies to Reviewer 2: Dr Lorraine Warrington 9. The authors have provided additional information about the intervention and control arms which is now much clearer. However this does clarify that patients do not receive any advice or guidance based on their responses and they are reliant on the clinician contacting them within 24 hours. This does raise ethical issues around patient safety. What safeguards are in place to ensure this contact happens, particularly around weekends etc? Under usual care, patients may be more likely to seek help through usual channels for symptoms themselves, but may be less likely if they have reported symptoms through the system. Are there potentially symptoms which would need earlier intervention? I think this needs addressing in the discussion.
Response: Thank you for your constructive suggestion. Both the intervention and control group patients will be informed that the routine symptom management will be maintained and the intervention is not a replacement of the regular symptom report approach. We have added "patients will be educated and allowed to seek medical help through usual channels for severe symptoms" in the revised manuscript to address the ethical issues relating to patient safety (Page 12). As a trial, a research team, including both attending physicians and nurses, is available to ensure the contact happens, whenever the weekdays or the weekends. 11. In relation to previous point 7, the purpose of involving patients in the development and design of studies goes far beyond establishing feasibility. I would refer the authors to a paper by Absolom et al 2015. I think this needs to be addressed as a limitation.
Response: Thanks very much for your recommendation of the paper written by Absolom K et al 2015.
We admit that the involvement of patients is more integral to a PRO study, although previous studies and our ongoing observational study have provided pilot data for the design and development of this trial in terms of feasibility and acceptability. This RCT is designed to test the efficacy of the PRO monitoring system. We will evaluate the effectiveness in a future pragmatic clinical trials (PCT), with patients' involvement in study design, conduct and interpretation. We have addressed this issue as a limitation # Fifth in the DISCUSSION section (Pages 17-18).
12. The withdrawal criteria has been clarifying to include patients 'continually not complying with the specialist's advice'. Arguably, this will be creating bias within the study and limit generalisability to a real world setting. Another point for the discussion.
Response: We agree that the withdrawal criteria will create selection bias and limit the external validity, although the strict criteria will ensure the compliance of this study. In the future, we will
